- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00369707
Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL
A Phase II Trial of Combination Bortezomib and Rituximab as Front-line Therapy for Low-grade Non-Hodgkin's Lymphoma
Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with rituximab may kill more cancer cells.
This phase II trial is studying how well giving bortezomib together with rituximab works as first-line therapy in treating patients with low-grade B-cell non-Hodgkin's lymphoma.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a multicenter, prospective study.
- Induction therapy: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15, and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and on day 1 of all subsequent courses. Treatment repeats every 35 days for 3 courses. Patients achieving a complete response, partial response, or stable disease proceed to maintenance therapy.
- Maintenance therapy: Beginning 6-8 weeks after induction therapy, patients receive bortezomib IV over 3-5 seconds and rituximab IV on day 1. Treatment repeats every 60 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Blood and tissue samples are collected at baseline and periodically during study treatment.
After completion of study therapy, patients are followed every 3 months for 2 years.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Florida
-
Miami, Florida, Verenigde Staten, 33136
- University of Miami Sylvester Comprehensive Cancer Center - Miami
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Northwestern University
-
Chicago, Illinois, Verenigde Staten, 60611-2998
- Hematology-Oncology Associates of Illinois
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19111-2497
- Fox Chase Cancer Center - Philadelphia
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Histologically confirmed low-grade B-lymphocyte non-Hodgkins lymphoma
- Life expectancy > 12 months
Exclusion Criteria:
- No known history of HIV infection
- No other active infection
- No peripheral neuropathy ≥ grade 2 within the past 14 days
- No uncontrolled hypertension
None of the following cardiac conditions:
- Myocardial infarction within the past 6 months
- No heart failure
- Uncontrolled angina
- Severe uncontrolled ventricular arrhythmias
- Electrocardiographic evidence of acute ischemia
- Active conduction system abnormalities
- No serious medical or psychiatric illness that would preclude study compliance
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No prior therapy for non-Hodgkins lymphoma
- No prior bortezomib or rituximab
- At least 3 weeks since prior chemotherapy, radiation therapy, immunotherapy, systemic anticancer biologic therapy, or anticancer hormonal therapy
- At least 2 weeks since prior investigational drugs
- No other concurrent systemic cytotoxic chemotherapy or investigational agents + No leukemia
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Bortezomib and Rituximab
On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab.
How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours.
During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22.
However, rituximab will only be given on day 1 of each cycle.
|
On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab.
How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours.
During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22.
However, rituximab will only be given on day 1 of each cycle.
Andere namen:
On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab.
How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours.
During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22.
However, rituximab will only be given on day 1 of each cycle.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Overall Response Rate (Complete Response and Partial Response) After Three Inductions Cycles of Treatment.
Tijdsspanne: At baseline and at the completion of 3 cycles of treatment where 1 cycle equals 35 days.
|
The primary objective of this study is to assess the overall response rate. Overall response rate at this time point will be defined as complete response [CR] plus partial response [PR]) after 3 cycles of bortezomib/rituximab induction therapy for patients with previously untreated low-grade, B-cell NHL. Complete response requires complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities (e.g., lactate dehydrogenase [LDH]) definitely assignable to NHL. There must also be complete disappearance of lymphoma involvement in the bone marrow (if initially present). Partial response (PR) requires 50% decrease in SPD of the six largest dominant nodes or nodal masses and no increase in the size of the other nodes, liver, or spleen. |
At baseline and at the completion of 3 cycles of treatment where 1 cycle equals 35 days.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Overall Response Rate After 1 Course of Induction Therapy
Tijdsspanne: At baseline and at the completion of cycle 1 (1 cycle =35 days)
|
Overall response rate (ORR) after 1 cycle of bortezomib/rituximab induction therapy. Overall response rate at this time point will be defined as complete response [CR] plus partial response [PR]) after 1 cycle of bortezomib/rituximab induction therapy for patients with previously untreated low-grade, B-cell NHL. Complete response requires complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities (e.g., lactate dehydrogenase [LDH]) definitely assignable to NHL. There must also be complete disappearance of lymphoma involvement in the bone marrow (if initially present). Partial response (PR) requires 50% decrease in SPD of the six largest dominant nodes or nodal masses and no increase in the size of the other nodes, liver, or spleen. |
At baseline and at the completion of cycle 1 (1 cycle =35 days)
|
Overall Response Rate After Completion of Maintenance Therapy
Tijdsspanne: At baseline and every 2 months during treatment of up to 3 cycles of induction (1 cycle =35days) and 4 cycles of maintenance (1 cycle =2 months) for up to 12 months.
|
Overall response rate at completion of bortezomib/rituximab maintenance therapy. Overall response rate at this time point will be defined as complete response [CR] plus partial response [PR]) after 3 cycles of bortezomib/rituximab induction therapy and up to 4 cycles of maintenance for patients with previously untreated low-grade, B-cell NHL. Complete response requires complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities (e.g., lactate dehydrogenase [LDH]) definitely assignable to NHL. There must also be complete disappearance of lymphoma involvement in the bone marrow (if initially present). Partial response (PR) requires 50% decrease in SPD of the six largest dominant nodes or nodal masses and no increase in the size of the other nodes, liver, or spleen. |
At baseline and every 2 months during treatment of up to 3 cycles of induction (1 cycle =35days) and 4 cycles of maintenance (1 cycle =2 months) for up to 12 months.
|
Duration of Overall Response
Tijdsspanne: Every 2 months for up to 12 months then every 6 months for 2 years and annually for 1 year
|
The duration of overall response is measured from the time measurement criteria are met for complete response (CR) or partial response (PR) (whichever is first recorded)until the first date that recurrent or progressive disease is objectively documented. Complete response requires complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities (e.g., lactate dehydrogenase [LDH]) definitely assignable to NHL. There must also be complete disappearance of lymphoma involvement in the bone marrow (if initially present). Partial response (PR) requires 50% decrease in SPD of the six largest dominant nodes or nodal masses and no increase in the size of the other nodes, liver, or spleen. Progressive disease (PD) requires the appearance of any new lesion or increase by > 50% in the size of previously involved sites. |
Every 2 months for up to 12 months then every 6 months for 2 years and annually for 1 year
|
Number of Patients That Experience Adverse Events With Bortezomib/Rituximab Combination Treatment
Tijdsspanne: Day 1 of each cycle and at the completion of cycles 1 and 3, during treatment up to 12 months
|
Assess the safety and tolerance of bortezomib/rituximab as induction and maintenance therapy. Data will be collected for grade 3 and grade 4 adverse events experienced by patients that are determined to be at least possibly related to at least one study drug. Toxicity data for bortezomib/rituximab will be collected on day 1 of every cycle (1 cycle = 35 days) for up to 7 cycles during treatment according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 3.0 (CTCAE v3.0). In general adverse events (AEs) will be graded according to the following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE |
Day 1 of each cycle and at the completion of cycles 1 and 3, during treatment up to 12 months
|
Tissue Evaluation
Tijdsspanne: At baseline and at response assessment 1 after induction part A, 2, after induction part B and 3, maintenance period.
|
Tissue microarray analysis from paraffin embedded tissue, gene expression profiling from frozen tissue (both from initial node biopsy collected/stored) and whole blood analysis of FCγR polymorphism
|
At baseline and at response assessment 1 after induction part A, 2, after induction part B and 3, maintenance period.
|
Correlation of Tumor Burden
Tijdsspanne: At the start of treatment and at Median follow up for all patients was 50 months (range 12-78 months) and on intent to treat, PFS and OS for all patients is reported at 4 years.
|
Correlation of tumor burden according to Groupe D'Etude des Lymphomes Follicularies (GELF) with recently developed Follicular Lymphoma International Prognostic Index (FLIPI) prognostic index. All patients enrolled in the study were required to have high tumor burden (HTB) as defined by GELF, where HTB is defined as representing higher risk disease and poorer outcomes than low tumor burden (LTB). Patients were put into low risk or high risk FLIPI groups. Low risk group with a score of 0-2 and high risk group with a score of 3-5. A FLIPI score of 0 to 1 = "low risk" with a 10 year overall survival of 70%. A score of 2= "intermediate risk" with a 10 year overall survival of 50%. Finally, a score of ≥ 3 is considered "high risk" with a 10 year overall survival of 35%. Data was collected in connection with high or low risk FLIPI and Progression Free Survival (PFS) or Overall Survival (OS) and is reported as percentage patient with high/low risk that are progression free or alive. |
At the start of treatment and at Median follow up for all patients was 50 months (range 12-78 months) and on intent to treat, PFS and OS for all patients is reported at 4 years.
|
Percentage of Patients With Treatment Failure
Tijdsspanne: Median follow up for all patients was 50 months and on intent to treat, TTF rate for all patients is reported at 4 years.
|
Time to Treatment Failure (TTF) rate measured, from the time of first treatment to disease progression, relapse, second tumor, death from any cause, treatment toxicity requiring termination from the study, or for any reason treatment is discontinued permanently.
|
Median follow up for all patients was 50 months and on intent to treat, TTF rate for all patients is reported at 4 years.
|
Progression Free Survival (PFS) Rate
Tijdsspanne: Median follow up for all patients was 50 months (range 12-78 months) and on intent to treat, PFS for all patients is reported at 4 years.
|
Progression Free Survival is measured from the time of first induction infusion to disease progression, relapse, second tumor, or death from any cause. Progressive disease (PD) requires the following:
|
Median follow up for all patients was 50 months (range 12-78 months) and on intent to treat, PFS for all patients is reported at 4 years.
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Andrew M. Evens, DO, MS, Northwestern University
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Neoplasmata
- Lymfoproliferatieve aandoeningen
- Lymfatische ziekten
- Immunoproliferatieve aandoeningen
- Lymfoom
- Lymfoom, non-Hodgkin
- Fysiologische effecten van medicijnen
- Antireumatische middelen
- Antineoplastische middelen
- Immunologische factoren
- Antineoplastische middelen, immunologisch
- Rituximab
- Bortezomib
Andere studie-ID-nummers
- NU 06H1
- STU00005335 (Andere identificatie: Northwestern University IRB)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Non-Hodgkin-lymfoom
-
Marker Therapeutics, Inc.WervingNon-Hodgkin lymfoom | Non-Hodgkin-lymfoom, volwassene | Non-Hodgkin-lymfoom, refractair | Non-Hodgkin-lymfoom, recidiverendVerenigde Staten
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Nog niet aan het wervenLymfoom | Lymfoom, non-Hodgkin | Non-Hodgkin-lymfoom | Non-Hodgkin lymfoom | Refractair B-cel non-Hodgkin-lymfoom | Refractair non-Hodgkin-lymfoom | Hoogwaardig B-cellymfoom | CZS lymfoom | Lymfomen Non-Hodgkin B-cel | Recidiverend non-Hodgkin-lymfoom | Lymfoom, Non-Hodgkin | Groot B-cellymfoom | Lymfoom, non-Hodgkin... en andere voorwaarden
-
Stanford UniversityNational Institutes of Health (NIH); AmgenVoltooidLymfoom, non-Hodgkin | Lymfomen: Non-Hodgkin | Lymfomen: non-Hodgkin perifere T-cel | Lymfomen: non-Hodgkin huidlymfoom | Lymfomen: non-Hodgkin diffuse grote B-cel | Lymfomen: non-Hodgkin folliculair / indolente B-cel | Lymfomen: non-Hodgkin-mantelcel | Lymfomen: non-Hodgkin marginale zone | Lymfomen...Verenigde Staten
-
Chongqing Precision Biotech Co., LtdWervingNon-Hodgkin lymfoom | Refractair non-Hodgkin-lymfoom | Recidiverend non-Hodgkin-lymfoomChina
-
Caribou Biosciences, Inc.WervingLymfoom | Lymfoom, non-Hodgkin | B-cel lymfoom | Non-Hodgkin lymfoom | Refractair B-cel non-Hodgkin-lymfoom | Recidiverend non-hodgkinlymfoom | B-cel non-Hodgkin-lymfoomVerenigde Staten, Australië, Israël
-
Mayo ClinicNog niet aan het wervenIndolent B-cel non-Hodgkin-lymfoom | Recidiverend indolent non-hodgkinlymfoom | Refractair indolent non-hodgkinlymfoom | Recidiverend indolent B-cel non-Hodgkin lymfoom | Refractair indolent B-cel non-Hodgkin lymfoomVerenigde Staten
-
Memorial Sloan Kettering Cancer CenterWervingNon-Hodgkin lymfoom | Non-Hodgkin-lymfoom, recidiverend | Non-Hodgkin-lymfoom refractairVerenigde Staten
-
City of Hope Medical CenterNational Cancer Institute (NCI)WervingRefractair B-cel non-Hodgkin-lymfoom | Recidiverend B-cel non-Hodgkin-lymfoom | Hoogwaardig B-cel non-Hodgkin-lymfoom | Intermediate graad B-cel non-Hodgkin-lymfoomVerenigde Staten
-
Joseph TuscanoSpectrum Pharmaceuticals, IncActief, niet wervendRecidiverend non-hodgkinlymfoom | Refractair non-hodgkinlymfoomVerenigde Staten
-
National Cancer Institute (NCI)WervingRefractair B-cel non-Hodgkin-lymfoom | Refractair T-cel non-Hodgkin-lymfoom | Recidiverend B-cel non-Hodgkin-lymfoom | Terugkerend getransformeerd non-Hodgkin-lymfoom | Recidiverend non-Hodgkin-lymfoom | Refractair non-Hodgkin-lymfoom | Recidiverend T-cel non-Hodgkin-lymfoom | Recidiverend primair... en andere voorwaardenVerenigde Staten
Klinische onderzoeken op Rituximab
-
Children's Oncology GroupNational Cancer Institute (NCI)Actief, niet wervendEBV-gerelateerde post-transplantatie lymfoproliferatieve stoornis | Monomorfe post-transplantatie lymfoproliferatieve stoornis | Polymorfe post-transplantatie lymfoproliferatieve stoornis | Terugkerende monomorfe lymfoproliferatieve stoornis na transplantatie | Terugkerende polymorfe lymfoproliferatieve... en andere voorwaardenVerenigde Staten
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WervingAnn Arbor stadium I graad 1 folliculair lymfoom | Ann Arbor stadium I graad 2 folliculair lymfoom | Ann Arbor stadium II graad 1 folliculair lymfoom | Ann Arbor stadium II graad 2 folliculair lymfoomVerenigde Staten
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Actief, niet wervendTerugkerend klein lymfocytisch lymfoom | Prolymfatische Leukemie | Terugkerende chronische lymfatische leukemieVerenigde Staten
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Actief, niet wervendRecidiverend graad 1 folliculair lymfoom | Recidiverend graad 2 folliculair lymfoom | Recidiverend mantelcellymfoom | Recidiverend marginale zone-lymfoom | Refractair B-cel non-Hodgkin-lymfoom | Terugkerend klein lymfocytisch lymfoom | Recidiverend B-cel non-Hodgkin-lymfoom | Recidiverend graad... en andere voorwaardenVerenigde Staten
-
National Cancer Institute (NCI)VoltooidAnn Arbor stadium III graad 1 folliculair lymfoom | Ann Arbor stadium III graad 2 folliculair lymfoom | Ann Arbor stadium IV graad 1 folliculair lymfoom | Ann Arbor stadium IV graad 2 folliculair lymfoom | Ann Arbor stadium II graad 3 aaneengesloten folliculair lymfoom | Ann Arbor stadium... en andere voorwaardenVerenigde Staten
-
Mabion SAParexelIngetrokken
-
National Cancer Institute (NCI)Actief, niet wervendRecidiverend mantelcellymfoom | Refractair B-cel non-Hodgkin-lymfoom | Recidiverend B-cel non-Hodgkin-lymfoom | Refractair mantelcellymfoomVerenigde Staten
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WervingChronische lymfatische leukemie/klein lymfatisch lymfoomVerenigde Staten
-
National Cancer Institute (NCI)Celgene CorporationActief, niet wervendAnn Arbor stadium III graad 1 folliculair lymfoom | Ann Arbor stadium III graad 2 folliculair lymfoom | Ann Arbor stadium IV graad 1 folliculair lymfoom | Ann Arbor stadium IV graad 2 folliculair lymfoom | Ann Arbor stadium II graad 3 aaneengesloten folliculair lymfoom | Ann Arbor stadium... en andere voorwaardenVerenigde Staten
-
National Cancer Institute (NCI)Actief, niet wervendStadium I chronische lymfatische leukemie | Stadium II chronische lymfatische leukemie | Stadium III chronische lymfatische leukemie | Stadium IV chronische lymfatische leukemieVerenigde Staten, Canada